Swami Nathan

Value & Access executive with 25+ years of progressive pharmaceutical leadership across Regeneron, Bristol Myers Squibb, NovoCure, Wyeth and Merck, spanning oncology, rare disease, vaccines, specialty biologics, medical devices and advanced therapies. Builds and leads enterprise Value & Access organizations — pricing, contracting, government pricing, Gross-to-Net, account management and market access strategy — that translate payer and health-system dynamics into patient access and profitable growth. Trusted advisor to executive and Commercial leadership teams, with hands-on ownership of U.S. government pricing compliance (Medicaid, Medicare, 340B), IDN/GPO account strategy, and Gross-to-Net/Deals Desk governance, alongside deep global pricing and reimbursement expertise.

Head, Global Pricing & Contracting - Regeneron

(2016-01)

• Provide executive leadership for enterprise-wide pricing, contracting and government pricing strategy across oncology, rare disease and advanced therapy portfolios.
• Own U.S. government pricing programs — Medicaid, Medicare, 340B and FSS — ensuring full compliance with federal and state pricing regulations and reporting requirements.
• Direct account management and contracting strategy with IDNs, GPOs and health systems, driving contract performance and access expansion for infused oncology and rare disease therapies.
• Serve as executive sponsor of the Gross-to-Net and Deals Desk governance process, ensuring disciplined decision-making on pricing, discounts and rebate investment.
• Serve as trusted advisor to senior executives on pricing, reimbursement, launch sequencing and commercialization decisions.
• Established enterprise pricing governance, business case development processes, pricing databases and executive dashboards improving strategic decision-making.
• Coach and develop global pricing and market access professionals while strengthening organizational capabilities.

Head, Global Market Access - NovoCure

(2015-01 - 2016-12)

• Built the company's global market access function supporting commercialization of Optune.
• Developed global pricing strategy, payer evidence plans and reimbursement frameworks across major international markets.
• Partnered with executive leadership to align clinical evidence, value communication and pricing strategy.

Director, Global Value & Access - Bristol Myers Squibb

(2006-01 - 2015-12)

• Led pricing strategy, contracting and reimbursement planning supporting multiple blockbuster oncology and specialty brands.
• Directed account strategy and contract negotiations with IDNs, GPOs and specialty distributors supporting launches of infused and injectable oncology therapies.
• Ensured pricing compliance with Medicaid Best Price, Medicare and 340B requirements across the oncology portfolio.
• Directed cross-functional global teams delivering launch pricing, payer evidence and commercialization strategies.
• Supported launches including Opdivo (nivolumab), Yervoy combinations, Orencia, Sprycel, Nulojix, Elotuzumab and Onglyza.
• Advanced pricing governance, financial modeling and executive decision-support capabilities.

Senior Director, Pricing & Reimbursement - Wyeth

(2004-01 - 2006-12)

• Directed global pricing strategy for vaccines and women's health portfolios.
• Collaborated with governments and reimbursement agencies on innovative funding and access strategies.

Director, Pricing & Policy - Merck & Co.

(1998-01 - 2004-12)

• Led pricing policy, reimbursement strategy and financial planning supporting global vaccine commercialization.
• Worked with PAHO, GAVI and the Gates Foundation on sustainable global access initiatives.

M.S. - Health Economics - University of Pompeu Fabra

Master of Public Health - Johns Hopkins Bloomberg School of Public Health

MBA - State University of New York at Buffalo

Bachelor of Engineering - Birla Institute of Technology and Science